Birchview Capital, LP Buys Yield10 Bioscience Inc, Clovis Oncology Inc, Workhorse Group Inc, Sells Masimo Corp, OncoMed Pharmaceuticals Inc, Accuray Inc

• New Purchases: YTEN, CLVS, AAAP,
• Added Positions: WKHS, VNDA, VCYT, VRML, GNMX,
• Reduced Positions: MASI, CELG, OMED, ARAY, CORT, TSRO,
• Sold Out: CHRS, CERS, BIVV,

For the details of Birchview Capital, LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Birchview+Capital%2C+LP

1. Celgene Corp (CELG) - 767,051 shares, 53.13% of the total portfolio. Shares reduced by 1.29%
2. Accelerate Diagnostics Inc (AXDX) - 2,183,795 shares, 29.42% of the total portfolio. Shares added by 0.37%
3. Vermillion Inc (VRML) - 2,752,933 shares, 3.14% of the total portfolio. Shares added by 1.30%
4. EQT Corp (EQT) - 42,300 shares, 1.44% of the total portfolio.
5. Biolase Inc (BIOL) - 1,285,903 shares, 0.97% of the total portfolio.

Birchview Capital, LP initiated holdings in Yield10 Bioscience Inc. The purchase prices were between $0.33 and $0.44, with an estimated average price of $0.37. The stock is now traded at around $0.47. The impact to the portfolio due to this purchase was 0.45%. The holdings were 2,263,166 shares as of 2017-03-31.

Birchview Capital, LP initiated holdings in Clovis Oncology Inc. The purchase prices were between $42.95 and $71.93, with an estimated average price of $60.79. The stock is now traded at around $49.38. The impact to the portfolio due to this purchase was 0.35%. The holdings were 10,000 shares as of 2017-03-31.

Birchview Capital, LP initiated holdings in Advanced Accelerator Applications SA. The purchase prices were between $27.16 and $40, with an estimated average price of $34.51. The stock is now traded at around $37.98. The impact to the portfolio due to this purchase was 0.16%. The holdings were 7,000 shares as of 2017-03-31.

Birchview Capital, LP added to the holdings in Workhorse Group Inc by 766.67%. The purchase prices were between $1.86 and $6.89, with an estimated average price of $3.47. The stock is now traded at around $2.62. The impact to the portfolio due to this purchase was 0.34%. The holdings were 260,000 shares as of 2017-03-31.

Birchview Capital, LP added to the holdings in Vanda Pharmaceuticals Inc by 145.45%. The purchase prices were between $13.05 and $15.95, with an estimated average price of $14.25. The stock is now traded at around $14.68. The impact to the portfolio due to this purchase was 0.25%. The holdings were 54,000 shares as of 2017-03-31.

Birchview Capital, LP added to the holdings in Aevi Genomic Medicine Inc by 41.67%. The purchase prices were between $1.6 and $6.05, with an estimated average price of $4.52. The stock is now traded at around $1.60. The impact to the portfolio due to this purchase was 0.02%. The holdings were 68,000 shares as of 2017-03-31.

Birchview Capital, LP sold out the holdings in Coherus BioSciences Inc. The sale prices were between $20.5 and $29.05, with an estimated average price of $24.6.

Birchview Capital, LP sold out the holdings in Cerus Corp. The sale prices were between $3.91 and $4.58, with an estimated average price of $4.24.

Birchview Capital, LP sold out the holdings in Bioverativ Inc. The sale prices were between $41.82 and $54.46, with an estimated average price of $47.97.